• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Advances in Sexual Medicine >Erectile Dysfunction among Diabetic Men in Two Medical Centers in Burkina Faso: Epidemiological, Diagnosis and Therapeutic Aspects
【24h】

Erectile Dysfunction among Diabetic Men in Two Medical Centers in Burkina Faso: Epidemiological, Diagnosis and Therapeutic Aspects

机译：布基纳法索两个医疗中心的糖尿病男性勃起功能障碍：流行病学，诊断和治疗方面

获取原文
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: To study erectile dysfunction in diabetic patients seen in two clinics in the city of Bobo-Dioulasso, Burkina Faso. Materials and Methods: A prospective cross-sectional descriptive study was conducted at the Souro Sanou Teaching Hospital (CHUSS) and the Saint Leopold clinic in Bobo-Dioulasso, from March 1 to September 1, 2012. A total of 107 patients data were collated and analysed, which was then grouped into two: the ED group, designating patients with erectile dysfunction and the NED group consisting of those patients without. The sample comprised of 61 patients with types 1 and 2 diabetesand were aged between 25-70 years. The IIEF-5 was used to evaluate erectile dysfunction. Results: The prevalence of erectile dysfunction was 57%. The average age of patients was 54.4 ± 8.3 years. All patients with ED had type 2 diabetes. The mean disease duration of diabetes was 7.2 ± 6 years. Erectile dysfunction was severe in 32.8% of cases, moderate in 31.1% of cases and mild in 36.1%. Its severity was significantly associated with glycated hemoglobin, triglycerides and BMI. Phosphodiesterase types 5 (PDE5) inhibitors were found to be effective in the treatment of erectile dysfunction with a satisfactory therapeutic response in 77.4% of users. Conclusion: Erectile dysfunction is a common complication in diabetic patients. Its occurrence and severity are influenced by several factors. The potential presence of this disorder should be assessed due to its negative impact on quality of life. Phosphodiesterase type 5 inhibitors are an effective treatment modality in diabetic patients.
机译：目的：研究在布基纳法索波波-迪乌拉索市的两家诊所中发现的糖尿病患者的勃起功能障碍。资料和方法：2012年3月1日至9月1日，在Bobo-Dioulasso的Souro Sanou教学医院（CHUSS）和Saint Leopold诊所进行了前瞻性横断面描述性研究。共收集了107例患者数据，进行分析，然后分为两个部分：ED组，指定勃起功能障碍患者; NED组，包括没有勃起功能障碍的患者。该样本包括61位1型和2型糖尿病患者，年龄在25-70岁之间。 IIEF-5用于评估勃起功能障碍。结果：勃起功能障碍的患病率为57％。患者的平均年龄为54.4±8.3岁。所有ED患者均患有2型糖尿病。糖尿病的平均病程为7.2±6年。勃起功能障碍严重的占32.8％，中度的占31.1％，轻度的占36.1％。其严重程度与糖化血红蛋白，甘油三酸酯和BMI显着相关。发现5型磷酸二酯酶（PDE5）抑制剂可有效治疗勃起功能障碍，在77.4％的用户中具有令人满意的治疗反应。结论：勃起功能障碍是糖尿病患者的常见并发症。它的发生和严重性受几个因素影响。由于其对生活质量的负面影响，应评估这种疾病的潜在存在。 5型磷酸二酯酶抑制剂是糖尿病患者的一种有效治疗方式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号